Equity Overview
Price & Market Data
Price: $12.13
Daily Change: -$0.175 / 1.44%
Daily Range: $11.99 - $12.37
Market Cap: $2,120,129,280
Daily Volume: 460,942
Performance Metrics
1 Week: 1.17%
1 Month: 8.84%
3 Months: 61.88%
6 Months: 57.85%
1 Year: 52.85%
YTD: 41.22%
Company Details
Employees: 274
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.